Table 1 Alemtuzumab patient and RA patient control demographic and serological data. CAM prefix denotes alemtuzumab treated patients and CON prefix denotes control patients. ^aTotal cumulative alemtuzumab dose administerd to RA patients between 1991–1994. ^bDAS-28-ESR at the baseline visit for this study; ^cVAS pain patient reported; ^dSJC: swollen joint count, range 0–28; ^eTJC: tender joint count, range 0–28; ^fIgG: normal range: 6-16 g/L; ^gIgA: normal range: 0.9-4.5 g/L; ^hIgM normal range: 0.5-2 g/L; ⁱRF titre by direct quantification, IU/ml; positive threshold 14 IU/ml; ^jCCP: anti-cyclic citrullinated peptide, U/ml, positive threshold 7 U/ml; ^kDMARD/Biological therapy: MTX - methotrexate; HCQ – hydroxychloroquine; LEF–leflunomide; SSZ-sulphasalazine; ABA–abatacept; ADA – adalimumab; ETA – etanercept; TOC – tocilizumab; n/a: not applicable

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies